Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives


Author index

Page Path
HOME > Articles and issues > Author index
Jeong-Min Seong 1 Article
Antiviral Activity of Itraconazole against Echovirus 30 Infection In Vitro
Jae-Sug Lee, Hwa-Jung Choi, Jae-Hyoung Song, Hyun-Jeong Ko, Kyungah Yoon, Jeong-Min Seong
Osong Public Health Res Perspect. 2017;8(5):318-324.   Published online October 31, 2017
  • 3,922 View
  • 24 Download
  • 7 Citations
AbstractAbstract PDF

Echovirus 30 is a major cause of meningitis in children and adults. The aim of this study was to investigate whether the antifungal drug itraconazole could exhibit antiviral activity against echovirus 30.


The cytopathic effect and viral RNA levels were assessed in RD cells as indicators of viral replication. The effects of itraconazole were compared to those of two known antiviral drugs, rupintrivir and pleconaril. The time course and time-of-addition assays were used to approximate the time at which itraconazole exerts its activity in the viral cycle.


Itraconazole and rupintrivir demonstrated the greatest potency against echovirus 30, demonstrating concentration-dependent activity, whereas pleconaril showed no antiviral activity. Itraconazole did not directly inactivate echovirus 30 particles or impede viral uptake into RD cells, but did affect the initial stages of echovirus 30 infection through interference with viral replication.


Itraconazole can be considered a lead candidate for the development of antiviral drugs against echovirus 30 that may be used during the early stages of echovirus 30 replication.


Citations to this article as recorded by  
  • Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances
    Chiara Tammaro, Michela Guida, Federico Appetecchia, Mariangela Biava, Sara Consalvi, Giovanna Poce
    Pharmaceuticals.2023; 16(2): 203.     CrossRef
  • Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery
    Leena Abdulaziz, Esraa Elhadi, Ejlal A Abdallah, Fadlalbaseer A Alnoor, Bashir A Yousef
    Journal of Experimental Pharmacology.2022; Volume 14: 97.     CrossRef
  • Identification of novel Ebola virus inhibitors using biologically contained virus
    Bert Vanmechelen, Joren Stroobants, Winston Chiu, Joost Schepers, Arnaud Marchand, Patrick Chaltin, Kurt Vermeire, Piet Maes
    Antiviral Research.2022; 200: 105294.     CrossRef
  • The Antifungal Itraconazole Is a Potent Inhibitor of Chikungunya Virus Replication
    Lucca Policastro, Isabela Dolci, Andre Godoy, José Silva Júnior, Uriel Ruiz, Igor Santos, Ana Jardim, Kirandeep Samby, Jeremy Burrows, Timothy Wells, Laura Gil, Glaucius Oliva, Rafaela Fernandes
    Viruses.2022; 14(7): 1351.     CrossRef
  • Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle
    Eric Rhoden, Terry Fei Fan Ng, Ray Campagnoli, W. Allan Nix, Jennifer Konopka-Anstadt, Rangaraj Selvarangan, Laurence Briesach, M. Steven Oberste, William C. Weldon
    Antimicrobial Agents and Chemotherapy.2020;[Epub]     CrossRef
  • Potential antiviral properties of antifungal drugs
    FalahH.O Al-Khikani, HudaA.S Almosawey, YounusJ Abdullah, AtyafA Al-Asadi, RaghdahM Hameed, NoorF Hasan, MohanadK.M Al-Ibraheemi
    Journal of the Egyptian Women's Dermatologic Socie.2020; 17(3): 185.     CrossRef
  • Repurposing approach identifies new treatment options for invasive fungal disease
    Isis Regina Grenier Capoci, Daniella Renata Faria, Karina Mayumi Sakita, Franciele Abigail Vilugron Rodrigues-Vendramini, Patricia de Souza Bonfim-Mendonça, Tania Cristina Alexandrino Becker, Érika Seki Kioshima, Terezinha Inez Estivalet Svidzinski, Berna
    Bioorganic Chemistry.2019; 84: 87.     CrossRef

PHRP : Osong Public Health and Research Perspectives